<DOC>
	<DOCNO>NCT00617929</DOCNO>
	<brief_summary>RATIONALE : Antithymocyte globulin , clofarabine , rituximab may stop patient 's immune system reject donor 's stem cell exactly match patient 's blood . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin transplant cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give antithymocyte globulin together clofarabine rituximab work treat patient unsuccessful stem cell transplant .</brief_summary>
	<brief_title>Antithymocyte Globulin , Clofarabine , Rituximab Treating Patients After Unsuccessful Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine rate sustain donor engraftment 42 day survival 100 day post transplantation patient treat anti-thymocyte globulin , clofarabine , rituximab . Secondary - To determine incidence treatment-related mortality day 100 post transplantation . - To determine incidence neutrophil recovery day 42 post transplantation . - To determine survival day 100 1 year post transplantation . - To determine proportion patient chimerism day 28 post transplantation . - To determine incidence severity grade II-IV acute graft-vs-host disease day 100 post transplantation . OUTLINE : - Conditioning regimen : Patients receive rituximab intravenously ( IV ) day -7 , anti-thymocyte globulin IV 4-6 hour day -6 -4 , clofarabine IV 1 hour day -4 -2 . - Hematopoietic stem cell transplantation ( HSCT ) : Patients undergo HSCT day 0 . Patients may receive umbilical cord blood , peripheral blood stem cell , bone marrow unrelated related donor . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive oral cyclosporine twice daily cyclosporine IV every 8 hour begin day -3 continue 100 180 day post transplantation follow taper ; mycophenolate mofetil IV every 8 hour begin day -3 continue 30 day ( 7 day engraftment evidence GVHD ) ; filgrastim ( G-CSF ) IV daily begin day 1 continue blood count recover . After completion study therapy , patient follow day 100 , 180 , 360 .</detailed_description>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Patient Timing relevant evaluation : Taking account need rapid intervention , white blood count le 200 day +20 , bone marrow aspirate perform day +21 . Unless increase absolute neutrophil count ( ANC ) &gt; 500 follow 7 day , bone marrow aspirate repeat day +28 . If white blood count still less 200 bone marrow acellular , bone marrow ( BM ) peripheral blood stem cell ( PBSC ) donor reactivate availability cord blood ( CB ) unit assess . If BM PBSC donor confirm within 14 day request donation ( typically second donation donor ) , CB unit use instead . Primary secondary graft failure hematopoietic stem cell transplantation define &gt; 50 % loss donor chimerism previous maximum le 25 % donor beyond day +42 pancytopenia evidence relapse . Patients diagnosis , type donor , hematopoietic cell graft condition regimen consider study . primary graft failure define : ANC &lt; 500 BM &lt; 10 % two occasion ( Day +21 Day +28 ) Donor chimerism need consider , provide evidence malignancy secondary graft failure define &lt; 5 % cellularity ANC &lt; 500 7 day time primary engraftment ) . Women childbearing potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment . Patients guardian able willing provide write informed consent . Patient The presence follow excludes patient study enrollment : Uncontrolled active infection define one week response appropriately choose antibiotic Evidence recurrence primary malignancy . Pregnant lactating . The agent use study may teratogenic fetus information excretion agent breast milk . All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy . Women childbearing age must use appropriate method describe . Allergy rituximab . Evidence HIV infection positive HIV serology . Autologous recovery define define great 90 % recipient PCR product competitive VNTR PCR perform gradually increase white blood cell count . Donor Related donor must 275 year age good health . Meets match criterion Able willing undergo cell collection procedure ( bone marrow cell collection leukapheresis ) Not pregnant lactating . HIV1 , HIV2 negative ; HTLV1 , HTLV2 negative , Hepatitis B C negative . Patients guardian able willing provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>lymphoblastic leukemia</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>lymphoblastic lymphoma</keyword>
	<keyword>breast cancer</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>